- Royalties of sales are split 50/50. BP is responsible for all further development and mass production of Brilacidin. Those cost will be deducted in full from the sales split.
Again, this is similar to the Pfizer deal structure. There it was:
In our case it'd be in everyone's interest that BP takes charge here 100%, obviously.
Remember, at the time of the deal the BioNTech vaccine was pre-clinical, we would close our deal after our clinical tests!
The BP could get a fully vetted solution just weeks away from EUA. Furthermore, Covid19 is obviously just the start. Our pipeline is already massive with candidates in Phase 2 trials (IBD) or even ready for Phase 3 (OM and ABSII). Aside from those already in development, imagine what a deep-pocketed BP could get out of Brilacidin in the coming years! From COPD to common cold, maybe even from Alzheimer to Fibromyalgia, the sky's the limit!
The financial risk for the BP is minimal and the upside potential unlimited.
Also, it guarantees that no other BP can get its hand on it!
This IMHO sounds like a deal both sides could be excited about!